{"schema_version":"1","generated_at":"2026-10-29T02:48:36.828Z","data_as_of":null,"url":"https://www.findmykol.com/kol/thomas-chauncey","json_url":"https://www.findmykol.com/kol/thomas-chauncey/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"thomas-chauncey","name":"Thomas Chauncey","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of Washington","institution_url":"https://www.findmykol.com/institution/university-of-washington","city":"Seattle","state":"WA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1710077243","orcid":"0000-0003-2815-7301","openalex":"A5045089433"},"summary":"Thomas Chauncey is an Oncology physician affiliated with University of Washington. OpenAlex indexes 220 publications with 16,003 citations (h-index 61); ClinicalTrials.gov lists 3 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the FindMyKOL directory.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":220,"cited_by_count":16003,"h_index":61,"latest_activity_year":2025,"citation_standing":{"top_percent":10,"cohort":"Hematology / Oncology","method":"https://www.findmykol.com/about#citation-standing"},"source":"works"},"trials":{"count":3,"shown":3,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT00066794","title":"S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"SWOG Cancer Research Network","source_url":"https://clinicaltrials.gov/study/NCT00066794","trial_url":"https://www.findmykol.com/trial/NCT00066794"},{"nct":"NCT00023777","title":"S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"SWOG Cancer Research Network","source_url":"https://clinicaltrials.gov/study/NCT00023777","trial_url":"https://www.findmykol.com/trial/NCT00023777"},{"nct":"NCT00004217","title":"S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"SWOG Cancer Research Network","source_url":"https://clinicaltrials.gov/study/NCT00004217","trial_url":"https://www.findmykol.com/trial/NCT00004217"}],"source":"trials"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":2,"shown":2,"withheld":0,"rows":[{"payer":"Daiichi Sankyo Inc.","program_year":2025,"amount_usd":650,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1710077243"},{"payer":"Janssen Biotech, Inc.","program_year":2023,"amount_usd":35.53,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1710077243"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1710077243","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","year":2019,"journal":"The Lancet Haematology","source_url":"https://doi.org/10.1016/s2352-3026(19)30088-2","status":"verified"},{"title":"Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation","year":2013,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2012.45.0247","status":"verified"},{"title":"Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose","year":2013,"journal":"Biology of Blood and Marrow Transplantation","source_url":"https://doi.org/10.1016/j.bbmt.2013.03.001","status":"verified"},{"title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","year":2012,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2011-08-372904","status":"verified"},{"title":"Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies","year":2011,"journal":"JAMA","source_url":"https://doi.org/10.1001/jama.2011.1558","status":"verified"}],"source":"works"},"contact":{"address_1":"1660 S COLUMBIAN WAY","address_2":"MARROW TRANSPLANT UNIT (111)","city":"Seattle","state":"WA","zip":"981081532","phone":"206-764-2969","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1710077243","source":"identity"},"similar":[{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Connie Celum","slug":"connie-celum","institution":"University of Washington","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/connie-celum","json_url":"https://www.findmykol.com/kol/connie-celum/profile.json"},{"name":"Helen Chu","slug":"helen-chu","institution":"University of Washington","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/helen-chu","json_url":"https://www.findmykol.com/kol/helen-chu/profile.json"},{"name":"Bryan Kestenbaum","slug":"bryan-kestenbaum","institution":"University of Washington","specialty":"Nephrology","url":"https://www.findmykol.com/kol/bryan-kestenbaum","json_url":"https://www.findmykol.com/kol/bryan-kestenbaum/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2007-07-08","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}